Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: J Steroid Biochem Mol Biol. 2017 Feb 1;173:157–167. doi: 10.1016/j.jsbmb.2017.01.024

Figure 8. RIPK1 depletion sensitizes cells to 1,25D3.

Figure 8

A. RIPK1 expression in wild-type (RIPK1+/+) and RIPK1-null (RIPK1−/−) MEFs was verified by Western blot analyses. B. MEFs were plated in 96-well plates and treated with either EtOH or indicated concentrations of 1,25D3 for 6 days. MTT assay was performed. Six samples were analyzed in parallel for each data point (n=6) and the experiment was repeated twice. Percentages of cell growth were first calculated by subtracting MTT values at day zero from those in day 6 followed by dividing with day zero values. Percentages of growth suppression by 1,25D3 were calculated by dividing percentages of cell growth in 1,25D3-treated groups with those of the EtOH controls. **p<0.005; ***p<0.001, ****p<0.0001. C. RIPK1 and VDR expression was determined by Western blot analyses in an OVCAR3 cell pool stably expressing control or RIPK1 shRNA. D. The OVCAR3 pools were treated with EtOH or 1,25D3 for 6 days and the percentage of growth suppression was measured in MTT assays as in Panel A. E. RIPK1 and VDR expression was determined by Western blot analyses in PE01 cell clones stably expressing control or RIPK1 shRNA. F. PE01 clones were treated with EtOH or 1,25D3 for 6 days and the percentage of growth suppression was determined in MTT assays as in Panel A.